2020
Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial
Berk J, Damy T, Drachman B, Elliott P, Gottlieb S, Grogan M, Gundapaneni B, Hanna M, Hoffman J, Hummel S, Judge D, Lenihan D, Merlini G, Patterson T, Rapezzi C, Schwartz J, Shah S, Sultan M, Velazquez E, Cruz M, Witteles R. Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart & Lung 2020, 49: 209-210. DOI: 10.1016/j.hrtlng.2020.02.009.Peer-Reviewed Original ResearchEfficacy of tafamidisSix-minute walk distanceATTR-CMCause mortalityQuality of lifeWalk distanceHeart failureKansas City Cardiomyopathy Questionnaire overall scorePre-specified sensitivity analysisSix-minute walk test distanceTransthyretin Cardiomyopathy Clinical TrialHard cardiovascular endpointsFirst-line therapyKey secondary endpointPrimary efficacy analysisTransthyretin amyloid cardiomyopathyOverall scoreMechanical assist devicesClinical laboratory testsNovel study designNYHA classTafamidis groupPlacebo groupSecondary endpointsAdverse events
2019
Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension
Shelburne NJ, Parikh KS, Chiswell K, Shaw LK, Sivak J, Arges K, Tomfohr J, Velazquez EJ, Kisslo J, Samad Z, Rajagopal S. Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. The American Journal Of Cardiology 2019, 124: 1298-1304. PMID: 31481176, DOI: 10.1016/j.amjcard.2019.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntihypertensive AgentsEchocardiographyExercise TestFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedNorth CarolinaPrognosisPulmonary Arterial HypertensionRetrospective StudiesSeverity of Illness IndexStroke VolumeSurvival RateVentricular Function, RightYoung AdultConceptsTricuspid annular plane systolic excursionPulmonary arterial hypertensionRV global longitudinal strainRV systolic pressureRight ventricular functionGlobal longitudinal strainArterial hypertensionSystolic pressureVentricular functionSevere pulmonary arterial hypertensionAnnular plane systolic excursionLongitudinal strainPAH-specific therapyManagement of patientsRight atrial areaMid-RVPAH therapyCause mortalityEchocardiographic parametersClinical responseEchocardiographic variablesSystolic excursionWalk distanceEchocardiographic assessmentAtrial area
2018
Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension
Siddiqui I, Rajagopal S, Brucker A, Chiswell K, Christopher B, Alenezi F, Mandawat A, Rivera D, Arges K, Tapson V, Kisslo J, Velazquez E, Douglas PS, Samad Z. Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension. The American Journal Of Cardiology 2018, 122: 872-878. PMID: 30093068, PMCID: PMC6280670, DOI: 10.1016/j.amjcard.2018.05.019.Peer-Reviewed Original ResearchConceptsPrecapillary pulmonary hypertensionRV global longitudinal strainPulmonary hypertensionEchocardiographic parametersHard outcomesPulmonary arterial hypertension medicationsClass III symptomsREVEAL risk scoreRight heart functionCohort of patientsCumulative incidence rateCurrent clinical guidelinesGlobal longitudinal strainEchocardiographic predictorsHypertension medicationsNT-proBNPTransthoracic echocardiographyWalk distanceUnivariable analysisMean ageClinical guidelinesIncidence rateMultivariable modelSurrogate outcomesRisk scoreSix-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy
Stewart RAH, Szalewska D, Stebbins A, Al-Khalidi HR, Cleland JGH, Rynkiewicz A, Drazner MH, White HD, Mark DB, Roy A, Kosevic D, Rajda M, Jasinski M, Leng CY, Tungsubutra W, Desvigne-Nickens P, Velazquez EJ, Petrie MC. Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart 2018, 5: e000752. PMID: 29531766, PMCID: PMC5845417, DOI: 10.1136/openhrt-2017-000752.Peer-Reviewed Original ResearchCoronary artery bypass surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionWalk distanceVentricular dysfunctionMedical therapyMED groupFunctional capacityNew York Heart Association classSix-minute walk distanceMin walk distanceCoronary artery bypassArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseArtery bypassBypass surgeryArtery diseaseAssociation classEjection fractionIschemic cardiomyopathySurgical treatmentTreatment allocationDisease trialsPatients
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacity
2014
Comprehensive Assessment of Right Ventricular Function in Patients with Pulmonary Hypertension with Global Longitudinal Peak Systolic Strain Derived from Multiple Right Ventricular Views
Rajagopal S, Forsha DE, Risum N, Hornik CP, Poms AD, Fortin TA, Tapson VF, Velazquez EJ, Kisslo J, Samad Z. Comprehensive Assessment of Right Ventricular Function in Patients with Pulmonary Hypertension with Global Longitudinal Peak Systolic Strain Derived from Multiple Right Ventricular Views. Journal Of The American Society Of Echocardiography 2014, 27: 657-665.e3. PMID: 24656881, DOI: 10.1016/j.echo.2014.02.001.Peer-Reviewed Original ResearchConceptsRV longitudinal peak systolic strainLongitudinal peak systolic strainPulmonary hypertensionRight ventricular functionRV functionPeak systolic strainFour-chamber viewRight ventricleRV dysfunctionClinical characteristicsWalk distanceVentricular functionSystolic strainGlobal longitudinal peak systolic strainTricuspid annular plane systolic excursionAssessment of PHMean pulmonary artery pressurePulmonary capillary wedge pressureRV myocardial performance indexAnnular plane systolic excursionRegional RV dysfunctionCapillary wedge pressurePulmonary artery pressureCohort of patientsMyocardial performance index
2013
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy